Tag Archives: Sarilumab Phase 3 Rheumatoid Arthritis Trial

Sanofi and Regeneron Pharmaceuticals presented positive results from Sarilumab Phase 3 Rheumatoid Arthritis Trial at European League Against Rheumatism Annual Congress in Paris

Posted on 16, June 2014 by

Both doses of investigational drug sarilumab met all three co-primary endpoints New data include major clinical response rates and ACR20 scores at 52 weeks Paris and Tarrytown, NY, 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, … Read the full press release →

Posted in France, Healthcare, Pharma & Biotech

Tagged , , ,